Genprex News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.05.20	Stock Alert: Genprex Shares Up 53% In Premarket (RTTNews)
05.05.20	Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies (Businesswire)
04.05.20	Genprex Issues April 2020 Shareholder Letter (Businesswire)
21.04.20	Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations (Businesswire)
24.03.20	Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders (Businesswire)
23.03.20	Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives (Businesswire)
03.03.20	Genprex to Present at the 2020 LD Micro Virtual Conference (Businesswire)
21.02.20	Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants (Businesswire)
19.02.20	Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants (Businesswire)
14.02.20	Stock Alert: Genprex Hits New 52-week High (RTTNews)
11.02.20	Stock Alert: Genprex (GNPX) (RTTNews)
11.02.20	Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes (Businesswire)
06.02.20	Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement (Businesswire)
05.02.20	Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC) (Businesswire)
03.02.20	Genprex to Present at NobleCon16 Investor Conference (Businesswire)
29.01.20	Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy (Businesswire)
28.01.20	Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering (Businesswire)
23.01.20	Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market (Businesswire)
22.01.20	First Drug For TED Secures Approval, TROV On Watch, EVOK Faces FDA In June (RTTNews)
21.01.20	Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer (Businesswire)
06.01.20	Genprex to Present at Biotech Showcase™ 2020 in San Francisco (Businesswire)
20.11.19	Genprex Announces $1.26 Million Registered Direct Offering (Businesswire)
19.11.19	Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers (Businesswire)
04.11.19	Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month (Businesswire)
11.10.19	Healthcare Stocks That Plunged To New Lows(CTXR,AUPH,AAC...) (RTTNews)
09.10.19	Genprex to Present at the MicroCap Rodeo Investor Conference (Businesswire)
07.10.19	Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support (Businesswire)
18.09.19	Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019 (Businesswire)
11.09.19	Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer (Businesswire)
05.09.19	Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference (Businesswire)
03.09.19	Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck (Businesswire)
21.08.19	Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference (Businesswire)
13.08.19	Genprex Demonstrates Growth and Expansion Through Recent Achievements (Businesswire)
06.08.19	Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program (Businesswire)
31.07.19	Genprex Begins Next Phase of Drug Branding Program (Businesswire)
01.07.19	Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer (Businesswire)
21.05.19	Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum (Businesswire)
08.05.19	Genprex Retains Addison Whitney for Drug Nomenclature Branding (Businesswire)
08.04.19	Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting (Businesswire)
27.02.19	Genprex Strengthens Senior Team and Continues to Advance Operations (Businesswire)
19.02.19	Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors (Businesswire)
23.01.19	Genprex to Present at NobleConXV in Fort Lauderdale, Florida (Businesswire)
03.01.19	PRAN Gets New Lease Of Life, ADIL On Watch, GNPX Abuzz (RTTNews)
27.06.18	SPHS Rebounds, ACHV Soars On New Data, PBYI Gains On CHMP Opinion, SPPI Abuzz (RTTNews)
31.05.18	Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program (PR Newswire)
29.05.18	Genprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell (PR Newswire)
23.05.18	Genprex To Present At Upcoming Investor And Industry Conferences (PR Newswire)
17.05.18	EBIO Gets New Name, Time To Check CHEK, ABAX Snapped Up, GNPX Up 34% In 2 Days (RTTNews)
16.05.18	MEIP Gets Funded, PFNX Riding High, GNPX Turns Heads (RTTNews)
08.05.18	Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’299.00	2.40 %	K V
Holcim	89.04	1.09 %	K V
Roche Hldg G	266.90	0.95 %	K V
ABB	49.88	0.81 %	K V
Novartis	90.96	0.63 %	K V
Givaudan	3’882.00	-0.54 %	K V
Zurich Insur Gr	547.20	-0.83 %	K V
Alcon	76.34	-1.14 %	K V
Logitech Intl	78.74	-1.43 %	K V
Geberit	505.80	-1.52 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Genprex Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten